Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.

V. Gurewich

DOI: https://doi.org/10.1016/S0735-1097(87)80423-0

IF: 24

1987-11-01

Journal of the American College of Cardiology

Abstract:

What problem does this paper attempt to address?

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy

Cai Zhang,Yuxia Liu

DOI: https://doi.org/10.3389/fimmu.2020.01295

IF: 7.3

2020-06-23

Frontiers in Immunology

Abstract:Checkpoint blockade therapy, for example using antibodies against CTLA-4 and PD-1/PD-L1, relieves T cells from the suppression by inhibitory checkpoints in the tumor microenvironment; thereby achieving good outcomes in the treatment of different cancer types. Like T cells, natural killer (NK) cell inhibitory receptors function as checkpoints for NK cell activation. Upon interaction with their cognate ligands on infected cells, tumor cells, dendritic cells and regulatory T cells, signals from these receptors severely affect NK cells' activation and effector functions, resulting in NK cell exhaustion. Checkpoint inhibition with antagonistic antibodies (Abs) can rescue NK cell exhaustion and arouse their robust anti-tumor capacity. Most notably, the response to anti-PD-1 therapy can be enhanced by the increased frequency and activation of NK cells, thereby increasing the overall survival of patients with multiple types of cancer. In addition, rescue of NK cell activity could enhance adaptive T cells' anti-tumor activity. Some antagonistic Abs (e.g., anti-TIGIT and anti-NKG2A monoclonal Abs) have extraordinary potential in cancer therapy, as evidenced by their induction of potent anti-tumor immunity through recovering both NK and T cell function. In this review, we summarize the dysfunction of NK cells in the tumor microenvironment and the key NK cell checkpoint receptors or molecules that control NK cell function. We particularly focus on recent advances in the most promising strategies through blockade of NK cell checkpoints or their combination with other approaches to more effectively reject tumors.

immunology
The NKG2A immune checkpoint — a new direction in cancer immunotherapy

Benjamin C. Creelan,Scott J. Antonia

DOI: https://doi.org/10.1038/s41571-019-0182-8

IF: 78.8

2019-03-01

Nature Reviews Clinical Oncology

Abstract:Inhibition of the NKG2A immune checkpoint restores natural killer cell and T cell effector function in preclinical cancer models. In addition, NKG2A blockade in combination with other therapeutic antibodies is showing encouraging responses in a subset of patients with metastatic colorectal or head and neck cancer. However, established biomarkers of response are lacking, and larger trials are needed to enable firm conclusions to be drawn about whether NKG2A inhibition complements existing immunotherapies.

oncology
Results of a multicenter phase II trial for older patients with c‐Kit‐positive acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (HR‐MDS) using low‐dose Ara‐C and Imatinib

F. Heidel,J. Cortes,F. Rücker,W. Aulitzky,L. Letvak,T. Kindler,C. Huber,H. Döhner,H. Kantarjian,T. Fischer

DOI: https://doi.org/10.1002/cncr.22471

IF: 6.9209

2007-03-01

Cancer

Abstract:Imatinib (IM) is a potent tyrosine kinase inhibitor of c‐Kit. c‐Kit is expressed in the majority of patients with acute myeloid leukemia (AML). Whereas clinical trials evaluating monotherapy with IM in AML revealed low response rates, Ara‐C and IM showed synergistic effects in vitro. This suggested evaluation of a combination treatment.
Immune Evasion and Therapeutic Opportunities Based on Natural Killer Cells.

Jinjin Zhang,Feifei Guo,Lingyu Li,Songling Zhang,Yufeng Wang

DOI: https://doi.org/10.21147/j.issn.1000-9604.2023.03.07

2023-01-01

Abstract:Natural killer (NK) cells can elicit an immune response against malignantly transformed cells without recognizing antigens, and they also exhibit cytotoxic effects and immune surveillance functions in tumor immunotherapy. Although several studies have shown the promising antitumor effects of NK cells in immunotherapy, their function is often limited in the tumor microenvironment because tumor cells can easily escape NK cell-induced death. Thus, for efficient tumor immunotherapy, the mechanism by which tumor cells escape NK cell-induced cytotoxicity must be fully understood. Various novel molecules and checkpoint receptors that mediate the disruption of NK cells in the tumor microenvironment have been discovered. In this review, we analyze and detail the major activating and inhibitory receptors on the surface of NK cells to delineate the mechanism by which tumor cells suppress NKG2D ligand expression and increase tumor receptor and inhibitory receptor expression [NKG2A, programmed cell death 1 (PD-1), and T-cell immunoglobulin and immunoreceptor tyrosine inhibitory motif (TIGIT)] on the NK cell surface, and thus inhibit NK cell activity. We also reviewed the current status of treatments based on these surface molecules. By comparing the therapeutic effects related to the treatment status and bypass mechanisms, we attempt to identify optimal single or combined treatments to suggest new treatment strategies for tumor immunotherapy.
Natural killer cells in cancer immunotherapy

DanRu Wang,LingYun Dou,LiHao Sui,Yiquan Xue,Sheng Xu

DOI: https://doi.org/10.1002/mco2.626

2024-06-15

Abstract:Natural killer (NK) cells, as innate lymphocytes, possess cytotoxic capabilities and engage target cells through a repertoire of activating and inhibitory receptors. Particularly, natural killer group 2, member D (NKG2D) receptor on NK cells recognizes stress-induced ligands-the MHC class I chain-related molecules A and B (MICA/B) presented on tumor cells and is key to trigger the cytolytic response of NK cells. However, tumors have developed sophisticated strategies to evade NK cell surveillance, which lead to failure of tumor immunotherapy. In this paper, we summarized these immune escaping strategies, including the downregulation of ligands for activating receptors, upregulation of ligands for inhibitory receptors, secretion of immunosuppressive compounds, and the development of apoptosis resistance. Then, we focus on recent advancements in NK cell immune therapies, which include engaging activating NK cell receptors, upregulating NKG2D ligand MICA/B expression, blocking inhibitory NK cell receptors, adoptive NK cell therapy, chimeric antigen receptor (CAR)-engineered NK cells (CAR-NK), and NKG2D CAR-T cells, especially several vaccines targeting MICA/B. This review will inspire the research in NK cell biology in tumor and provide significant hope for improving cancer treatment outcomes by harnessing the potent cytotoxic activity of NK cells.
NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody

Ying Gong,Wilfred T V Germeraad,Xulin Zhang,Nisha Wu,Bo Li,Lynn Janssen,Zongzhong He,Marion J J Gijbels,Bodeng Wu,Birgit L M G Gijsbers,Timo I Olieslagers,Gerard M J Bos,Lei Zheng,Roel G J Klein Wolterink

DOI: https://doi.org/10.1016/j.ymthe.2024.06.034

2024-08-07

Abstract:Natural killer (NK) cells eliminate infected or cancer cells via their cytotoxic capacity. NKG2A is an inhibitory receptor on NK cells and cancer cells often overexpress its ligand HLA-E to evade NK cell surveillance. Given the successes of immune checkpoint blockade in cancer therapy, NKG2A is an interesting novel target. However, anti-NKG2A antibodies have shown limited clinical response. In the pursuit of enhancing NK cell-mediated anti-tumor responses, we devised a Cas9-based strategy to delete KLRC1, encoding NKG2A, in human primary NK cells. Our approach involved electroporation of KLRC1-targeting Cas9 ribonucleoprotein resulting in effective ablation of NKG2A expression. Compared with anti-NKG2A antibody blockade, NKG2AKO NK cells exhibited enhanced activation, reduced suppressive signaling, and elevated expression of key transcription factors. NKG2AKO NK cells overcame inhibition from HLA-E, significantly boosting NK cell activity against solid and hematologic cancer cells. We validated this efficacy across multiple cell lines, a xenograft mouse model, and primary human leukemic cells. Combining NKG2A knockout with antibody coating of tumor cells further enhanced cytotoxicity through ADCC. Thus, we provide a comprehensive comparison of inhibition of the NKG2A pathway using genetic ablation and antibodies and provide novel insight in the observed differences in molecular mechanisms, which can be translated to enhance adoptive NK cell immunotherapy.
NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances

Marco Greppi,Fabiana De Franco,Valentina Obino,Federico Rebaudi,Rayan Goda,Davide Frumento,Giorgio Vita,Camilla Baronti,Ombretta Melaiu,Matteo Bozzo,Simona Candiani,Valerio G Vellone,Federica Papaccio,Silvia Pesce,Emanuela Marcenaro

DOI: https://doi.org/10.1016/j.imlet.2024.106932

2024-09-18

Abstract:Natural Killer (NK) cells are integral to the innate immune system, renowned for their ability to target and eliminate cancer cells without the need for antigen presentation, sparing normal tissues. These cells are crucial in cancer immunosurveillance due to their diverse array of activating and inhibitory receptors that modulate their cytotoxic activity. However, the tumor microenvironment can suppress NK cell function through various mechanisms. Over recent decades, research has focused on overcoming these tumor escape mechanisms. Initially, efforts concentrated on enhancing T cell activity, leading to impressive results with immunotherapeutic approaches aimed at boosting T cell responses. Nevertheless, a substantial number of patients do not benefit from these treatments and continue to seek effective alternatives. In this context, NK cells present a promising avenue for developing new treatments, given their potent cytotoxic capabilities, safety profile, and activity against T cell-resistant tumors, such as those lacking HLA-I expression. Recent advancements in immunotherapy include strategies to restore and amplify NK cell activity through immune checkpoint inhibitors, cytokines, adoptive NK cell therapy, and CAR-NK cell technology. This review provides a comprehensive overview of NK cell receptors, the tumor escape mechanisms that hinder NK cell function, and the evolving field of NK cell-based cancer immunotherapy, highlighting ongoing efforts to develop more effective and targeted cancer treatment strategies.
Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment

Raj Kumar,Romi Gupta

DOI: https://doi.org/10.3389/fonc.2024.1456631

2024-08-05

Abstract:Epigenetic modifications influence gene expression and effects cancer initiation and progression. Therefore, they serve as diagnostic and prognostic biomarkers and potential therapeutic targets. Natural Killer (NK) cells, integral to the innate immune system, exhibit anti-tumor effect by recognizing and eliminating cancerous cells through the balance of activating and inhibitory ligands. Understanding the epigenetic regulation of NK cell ligands offers insights into enhancing NK cell-mediated tumor eradication. This review explores the epigenetic modifications governing the expression of activating NKG2D ligands and discusses clinical trials investigating NK cell-based immunotherapies, highlighting their potential as effective cancer treatment strategies. Case studies examining the safety and effectiveness of NK cell therapies in different cancer types, such as acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC), demonstrate promising outcomes with minimal toxicity. These findings underscore the therapeutic prospects of epigenetic modulation of NKG2D ligands and NK cell-based immunotherapies as effective cancer treatment strategies. Future research in the advancement of personalized medicine approaches and novel combination therapies with NK cell will further improve treatment outcomes and provide new therapeutic options for treating patients with various types of cancer.
NK Cell-Based Immune Checkpoint Inhibition

Muhammad Khan,Sumbal Arooj,Hua Wang

DOI: https://doi.org/10.3389/fimmu.2020.00167

IF: 7.3

2020-02-13

Frontiers in Immunology

Abstract:Immunotherapy, with an increasing number of therapeutic dimensions, is becoming an important mode of treatment for cancer patients. The inhibition of immune checkpoints, which are the source of immune escape for various cancers, is one such immunotherapeutic dimension. It has mainly been aimed at T cells in the past, but NK cells are a newly emerging target. Simultaneously, the number of checkpoints identified has been increasing in recent times. In addition to the classical NK cell receptors KIRs, LIRs, and NKG2A, several other immune checkpoints have also been shown to cause dysfunction of NK cells in various cancers and chronic infections. These checkpoints include the revolutionized CTLA-4, PD-1, and recently identified B7-H3, as well as LAG-3, TIGIT & CD96, TIM-3, and the most recently acknowledged checkpoint-members of the Siglecs family (Siglec-7/9), CD200 and CD47. An interesting dimension of immune checkpoints is their candidacy for dual-checkpoint inhibition, resulting in therapeutic synergism. Furthermore, the combination of immune checkpoint inhibition with other NK cell cytotoxicity restoration strategies could also strengthen its efficacy as an antitumor therapy. Here, we have undertaken a comprehensive review of the literature to date regarding NK cell-based immune checkpoints.

immunology
Tumor Immune Checkpoints and Their Associated Inhibitors

Zerui Gao,Xingyi Ling,Chengyu Shi,Ying Wang,Aifu Lin

DOI: https://doi.org/10.1631/jzus.b2200195

2022-01-01

Abstract:Immunological evasion is one of the defining characteristics of cancers, as the immune modification of an immune checkpoint (IC) confers immune evasion capabilities to tumor cells. Multiple ICs, such as programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), can bind to their respective receptors and reduce tumor immunity in a variety of ways, including blocking immune cell activation signals. IC blockade (ICB) therapies targeting these checkpoint molecules have demonstrated significant clinical benefits. This is because antibody-based IC inhibitors and a variety of specific small molecule inhibitors can inhibit key oncogenic signaling pathways and induce durable tumor remission in patients with a variety of cancers. Deciphering the roles and regulatory mechanisms of these IC molecules will provide crucial theoretical guidance for clinical treatment. In this review, we summarize the current knowledge on the functional and regulatory mechanisms of these IC molecules at multiple levels, including epigenetic regulation, transcriptional regulation, and post-translational modifications. In addition, we provide a summary of the medications targeting various nodes in the regulatory pathway, and highlight the potential of newly identified IC molecules, focusing on their potential implications for cancer diagnostics and immunotherapy.
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications

Simona Sivori,Paola Vacca,Genny Del Zotto,Enrico Munari,Maria Cristina Mingari,Lorenzo Moretta

DOI: https://doi.org/10.1038/s41423-019-0206-4

2019-02-18

Cellular and Molecular Immunology

Abstract:NK cells play important roles in innate defenses against viruses and in the control of tumor growth and metastasis. The regulation/induction of NK cell function is mediated by an array of activating or inhibitory surface receptors. In humans, major activating receptors involved in target cell killing are the natural cytotoxicity receptors (NCRs) and NKG2D. Activating receptors recognize ligands that are overexpressed or expressed de novo upon cell stress, viral infection, or tumor transformation. The HLA-class I-specific inhibitory receptors, including KIRs recognizing HLA-class I allotypic determinants and CD94/NKG2A recognizing the class-Ib HLA-E, constitute a fail-safe mechanism to avoid unwanted NK-mediated damage to healthy cells. Other receptors such as PD-1, primarily expressed by activated T lymphocytes, are important inhibitory checkpoints of immune responses that ensure T-cell tolerance. PD-1 also may be expressed by NK cells in cancer patients. Since PD-1 ligand (PD-L1) may be expressed by different tumors, PD-1/PD-L1 interactions inactivate both T and NK cells. Thus, the reliable evaluation of PD-L1 expression in tumors has become a major issue to select patients who may benefit from therapy with mAbs disrupting PD-1/PD-L1 interactions. Recently, NKG2A was revealed to be an important checkpoint controlling both NK and T-cell activation. Since most tumors express HLA-E, mAbs targeting NKG2A has been used alone or in combination with other therapeutic mAbs targeting PD-1 or tumor antigens (e.g., EGFR), with encouraging results. The translational value of NK cells and their receptors is evidenced by the extraordinary therapeutic success of haploidentical HSCT to cure otherwise fatal high-risk leukemias.

immunology
Natural killer group 2D receptor and its ligands in cancer immune escape

Shixin Duan,Weihua Guo,Zuxing Xu,Yunbo He,Chuting Liang,Yongzhen Mo,Yian Wang,Fang Xiong,Can Guo,Yong Li,Xiaoling Li,Guiyuan Li,Zhaoyang Zeng,Wei Xiong,Fuyan Wang

DOI: https://doi.org/10.1186/s12943-019-0956-8

IF: 37.3

2019-02-27

Molecular Cancer

Abstract:The immune system plays important roles in tumor development. According to the immune-editing theory, immune escape is the key to tumor survival, and exploring the mechanisms of tumor immune escape can provide a new basis for the treatment of tumors. In this review, we describe the mechanisms of natural killer group 2D (NKG2D) receptor and NKG2D ligand (NKG2DL) in tumor immune responses.Natural killer (NK) cells are important cytotoxic cells in the immune system, and the activated NKG2D receptor on the NK cell surface can bind to NKG2DL expressed in tumor cells, enabling NK cells to activate and kill tumor cells. However, tumors can escape the immune clearance mediated by NKG2D receptor/NKG2DL through various mechanisms. The expression of NKG2D receptor on NK cells can be regulated by cells, molecules, and hypoxia in the tumor microenvironment. Tumor cells regulate the expression of NKG2DL at the level of transcription, translation, and post-translation and thereby escape recognition by NK cells. In particular, viruses and hormones have special mechanisms to affect the expression of NKG2D receptor and NKG2DL. Therefore, NKG2DNKG2DL may have applications as targets for more effective antitumor therapy.

oncology,biochemistry & molecular biology
NK Cell Dysfunction and Checkpoint Immunotherapy

Jiacheng Bi,Zhigang Tian

DOI: https://doi.org/10.3389/fimmu.2019.01999

IF: 7.3

2019-01-01

Frontiers in Immunology

Abstract:NK cells play important roles in the innate immune responses against tumors. The effector function of NK cells relies on the integration of activating and inhibitory signals. Emerging checkpoint receptors and molecules are being revealed to mediate NK cell dysfunction in the tumor microenvironment. Inhibition of some NK cell surface checkpoint receptors has displayed the potential to reverse NK cell dysfunction in tumors, and to boost anti-tumor immunity, both in clinical trials (anti-KIR and anti-NKG2A), and in preclinical studies (e.g., anti-TIGIT, and anti-CD96). To fully exploit the potential of NK-based checkpoint immunotherapy, more understanding of the regional features of NK cells in the tumor microenvironment is required. This will provide valuable information regarding the dynamic nature of NK cell immune response against tumors, as well as novel checkpoints or pathways to be targeted. In this Review, we discuss recent advances in the understanding of NK cell dysfunction in tumors, as well as emerging strategies of NK-based checkpoint immunotherapy for tumors.
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches

Sebastian Carotta

DOI: https://doi.org/10.3389/fimmu.2016.00152

IF: 7.3

2016-04-21

Frontiers in Immunology

Abstract:The recent success of checkpoint blockade has highlighted the potential of immunotherapy approaches for cancer treatment. Although the majority of approved immunotherapy drugs target T cell subsets, it is appreciated that other components of the immune system have important roles in tumor immune surveillance as well and thus represent promising additional targets for immunotherapy. Natural killer (NK) cells are the body's first line of defense against infected or transformed cells, as they kill target cells in an antigen-independent manner. Although several studies have clearly demonstrated the active role of NK cells in cancer immune surveillance, only few clinically approved therapies currently exist that harness their potential. Our increased understanding of NK cell biology over the past few years has renewed the interest in NK cell-based anticancer therapies, which has lead to a steady increase of NK cell-based clinical and preclinical trials. Here, the role of NK cells in cancer immune surveillance is summarized, and several novel approaches to enhance NK cell cytotoxicity against cancer are discussed.

immunology
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer

Kathleen Ducoin,Romain Oger,Linda Bilonda Mutala,Cécile Deleine,Nicolas Jouand,Juliette Desfrançois,Juliette Podevin,Emilie Duchalais,Jonathan Cruard,Houssem Benlalam,Nathalie Labarrière,Céline Bossard,Anne Jarry,Nadine Gervois-Segain

DOI: https://doi.org/10.1080/2162402X.2022.2046931

2022-03-11

OncoImmunology

Abstract:Recently, the inhibitory CD94/NKG2A receptor has joined the group of immune checkpoints (ICs) and its expression has been documented in NK cells and CD8 + T lymphocytes in several cancers and some infectious diseases. In colorectal cancer (CRC), we previously reported that NKG2A + tumor-infiltrating lymphocytes (TILs) are predominantly CD8 + αβ T cells and that CD94 overexpression and/or its ligand HLA-E were associated with a poor prognosis. This study aimed to thoroughly characterize the NKG2A + CD8 + TIL subpopulation and document the impact of NKG2A on anti-tumor responses in CRC. Our findings highlight new features of this subpopulation: (i) enrichment in colorectal tumors compared to paired normal colonic mucosa, (ii) their character as tissue-resident T cells and their majority terminal exhaustion status, (iii) co-expression of other ICs delineating two subgroups differing mainly in the level of NKG2A expression and the presence of PD-1, (iv) high functional avidity despite reduced proliferative capacity and finally (v) inhibition of anti-tumor reactivity that is overcome by blocking NKG2A. From a clinical point of view, these results open a promising alternative for immunotherapies based on NKG2A blockade in CRC, which could be performed alone or in combination with other IC inhibitors, adoptive cell transfer or therapeutic vaccination. Graphical

oncology,immunology
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells

Silvia Pesce,Marco Greppi,Francesco Grossi,Genny Del Zotto,Lorenzo Moretta,Simona Sivori,Carlo Genova,Emanuela Marcenaro

DOI: https://doi.org/10.3389/fimmu.2019.01242

IF: 7.3

2019-06-04

Frontiers in Immunology

Abstract:The identification of inhibitory NK cell receptors specific for HLA-I molecules (KIRs and NKG2A) provided the molecular basis for clarifying the mechanism by which NK cells kill transformed cells while sparing normal cells. The direct interactions between inhibitory NK cell receptors and their HLA-I ligands enable NK cells to distinguish healthy from transformed cells, which frequently show an altered expression of HLA-I molecules. Indeed, NK cells can kill cancer cells that have lost, or under express, HLA-I molecules, but not cells maintaining their expression. In this last case, it is possible to use anti-KIR or anti-NKG2A monoclonal antibodies to block the inhibitory signals generated by these receptors and to restore the anti-tumor NK cell activity. These treatments fall within the context of the new immunotherapeutic strategies known as "immune checkpoint blockade." These antibodies are currently used in clinical trials in the treatment of both hematological and solid tumors. However, a more complex scenario has recently emerged. For example, NK cells can also express additional immune checkpoints, including PD-1, that was originally described on T lymphocytes, and whose ligands (PD-Ls) are usually overexpressed on tumor cells. Thus, it appears that the activation of NK cells and their potentially harmful effector functions are under the control of different immune checkpoints and their simultaneous expression could provide additional levels of suppression to anti-tumor NK cell responses. This review is focused on PD-1 immune checkpoint in NK cells, its potential role in immunosuppression, and the therapeutic strategies to recover NK cell cytotoxicity and anti-tumor effect.

immunology
Human endogenous retrovirus-H long terminal repeat-associating 2: an emerging immune checkpoint for cancer immunotherapy

Zeya Cao,Youping Wang,Shih-Chin Cheng,Nanhai He

DOI: https://doi.org/10.1093/jleuko/qiae158

2024-07-08

Journal of Leukocyte Biology

Abstract:Abstract Human endogenous retrovirus-H long terminal repeat-associating 2 (HHLA2), a member of the B7 family of co-signaling molecules, is aberrantly expressed in various human cancers and has emerged as a promising target for cancer immunotherapy. It exhibits a unique structure and tissue distribution pattern compared to other B7 family members, where its expression is regulated by the complex physiological and tumor microenvironment. HHLA2 plays a crucial but contradictory role in immune modulation and is thereby associated with heterogeneous prognostic implications across different cancer types. It interacts with two distinct receptors: transmembrane and immunoglobulin domain-containing 2 (TMIGD2), which is predominantly expressed on naïve T and natural killer (NK) cells to deliver co-stimulatory signals to T cells and NK cells, and killer cell immunoglobulin-like receptor, three immunoglobulin domains, and long cytoplasmic tail (KIR3DL3), which is prevalent on terminally differentiated T and CD56dim CD16+ NK cells to transmit inhibitory signals. The expression dynamics of these receptors on immune cells contribute to the maintenance of immune response homeostasis. Therapeutic strategies targeting the HHLA2 immune checkpoint aim to selectively inhibit the immunosuppressive HHLA2–KIR3DL3 pathway while preserving the HHLA2–TMIGD2 signaling. Several anti-HHLA2 and anti-KIR3DL3 antibodies are currently under investigation in early clinical trials, building upon encouraging results observed in humanized mouse models. Notably, the nonoverlapping expression of HHLA2 and PD-L1 in tumors suggests potential synergistic benefits of combining HHLA2–KIR3DL3-targeted therapies with PD-1/PD-L1 blockade or anti-CTLA-4 to augment antitumor activity.

immunology,cell biology,hematology
Measurement of 201Tl-concentration in myocardial biopsies from patients with cardiomyopathy and other forms of heart disease.

S. Mattsson,F. Hansen,B. Lilja,C. Pettersson,A. Torp

1978-04-01

Abstract:
Intracellular checkpoints for NK cell cancer immunotherapy

Yingying Huang,Zhigang Tian,Jiacheng Bi

DOI: https://doi.org/10.1007/s11684-024-1090-6

2024-09-30

Frontiers of Medicine

Abstract:Natural killer (NK) cells are key innate immune lymphocytes, which play important roles against tumors. However, tumor-infiltrating NK cells are always hypofunctional/exhaustive. On the one hand, this state is contributed by context-dependent interactions between inhibitory NK cell checkpoint receptors and their ligands, which usually vary in different tumor types and stages during tumor development. On the other hand, the inhibitory functions of intracellular checkpoint molecules of NK cells are more similar across different tumor types, representing common mechanisms limiting the potential of NK cell therapy. In this review, representative NK cell intracellular checkpoint molecules in different aspects of NK cell biology were reviewed, and therapeutic potentials were discussed by targeting these molecules to promote antitumor NK cell therapy.

oncology,medicine, research & experimental
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity

Aurelie Herault,Judy Mak,Josefa de la Cruz-Chuh,Michael A Dillon,Diego Ellerman,MaryAnn Go,Ely Cosino,Robyn Clark,Emily Carson,Stacey Yeung,Melanie Pichery,Mylène Gador,Eugene Y Chiang,Jia Wu,Yuxin Liang,Zora Modrusan,Gautham Gampa,Jawahar Sudhamsu,Christopher C Kemball,Victoria Cheung,Thi Thu Thao Nguyen,Dhaya Seshasayee,Robert Piskol,Klara Totpal,Shang-Fan Yu,Genee Lee,Katherine R Kozak,Christoph Spiess,Kevin B Walsh

DOI: https://doi.org/10.1007/s00262-024-03795-2

2024-08-08

Abstract:Background: Cancer immunotherapy approaches that elicit immune cell responses, including T and NK cells, have revolutionized the field of oncology. However, immunosuppressive mechanisms restrain immune cell activation within solid tumors so additional strategies to augment activity are required. Methods: We identified the co-stimulatory receptor NKG2D as a target based on its expression on a large proportion of CD8+ tumor infiltrating lymphocytes (TILs) from breast cancer patient samples. Human and murine surrogate NKG2D co-stimulatory receptor-bispecifics (CRB) that bind NKG2D on NK and CD8+ T cells as well as HER2 on breast cancer cells (HER2-CRB) were developed as a proof of concept for targeting this signaling axis in vitro and in vivo. Results: HER2-CRB enhanced NK cell activation and cytokine production when co-cultured with HER2 expressing breast cancer cell lines. HER2-CRB when combined with a T cell-dependent-bispecific (TDB) antibody that synthetically activates T cells by crosslinking CD3 to HER2 (HER2-TDB), enhanced T cell cytotoxicity, cytokine production and in vivo antitumor activity. A mouse surrogate HER2-CRB (mHER2-CRB) improved in vivo efficacy of HER2-TDB and augmented NK as well as T cell activation, cytokine production and effector CD8+ T cell differentiation. Conclusion: We demonstrate that targeting NKG2D with bispecific antibodies (BsAbs) is an effective approach to augment NK and CD8+ T cell antitumor immune responses. Given the large number of ongoing clinical trials leveraging NK and T cells for cancer immunotherapy, NKG2D-bispecifics have broad combinatorial potential.

Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy

The NKG2A immune checkpoint — a new direction in cancer immunotherapy

Results of a multicenter phase II trial for older patients with c‐Kit‐positive acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (HR‐MDS) using low‐dose Ara‐C and Imatinib

Immune Evasion and Therapeutic Opportunities Based on Natural Killer Cells.

Natural killer cells in cancer immunotherapy

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody

NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances

Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment

NK Cell-Based Immune Checkpoint Inhibition

Tumor Immune Checkpoints and Their Associated Inhibitors

Human NK cells: surface receptors, inhibitory checkpoints, and translational applications

Natural killer group 2D receptor and its ligands in cancer immune escape

NK Cell Dysfunction and Checkpoint Immunotherapy

Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches

Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells

Human endogenous retrovirus-H long terminal repeat-associating 2: an emerging immune checkpoint for cancer immunotherapy

Measurement of 201Tl-concentration in myocardial biopsies from patients with cardiomyopathy and other forms of heart disease.

Intracellular checkpoints for NK cell cancer immunotherapy

NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity